Johnson & Johnson $JNJ Shares Bought by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 216,409 shares of the company’s stock after buying an additional 3,079 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Johnson & Johnson were worth $33,057,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. W.H. Cornerstone Investments Inc. lifted its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock worth $1,206,000 after purchasing an additional 58 shares during the last quarter. Greenup Street Wealth Management LLC raised its stake in Johnson & Johnson by 3.1% in the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after buying an additional 60 shares in the last quarter. Ellis Investment Partners LLC lifted its holdings in Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after buying an additional 62 shares during the last quarter. Cypress Wealth Services LLC boosted its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after acquiring an additional 62 shares in the last quarter. Finally, Horizon Bancorp Inc. IN increased its holdings in shares of Johnson & Johnson by 11.2% in the 2nd quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after acquiring an additional 64 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.4%

Shares of Johnson & Johnson stock opened at $196.00 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market capitalization of $472.22 billion, a P/E ratio of 18.92, a PEG ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $197.18. The company’s fifty day moving average is $185.81 and its two-hundred day moving average is $170.04.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 15th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a research note on Monday, October 20th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.